Cipepofol

Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABAA receptor. Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol (HY-B0649) . Cipepofol can activate the sirtuin1 (Sirt1) /Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468) -induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis[1][2].

Product Specifications

CAS Number

[1637741-58-2]

Product Name Alternative

Ciprofol; HSK3486

UNSPSC

12352005

Target

Apoptosis; GABA Receptor; Keap1-Nrf2; Sirtuin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/cipepofol.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C1=CC=CC([C@@H](C2CC2)C)=C1O)C

Molecular Formula

C14H20O

Molecular Weight

204.31

References & Citations

[1]Ming Lu, et al. Ciprofol: A Novel Alternative to Propofol in Clinical Intravenous Anesthesia? Biomed Res Int. 2023 Jan 19:2023:7443226.|[2]Yunzhao Yang, et al. Ciprofol attenuates the isoproterenol-induced oxidative damage, inflammatory response and cardiomyocyte apoptosis. Front Pharmacol. 2022 Nov 22:13:1037151.